Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01990261
  4. Details
NCT01990261 Clinical Trial

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment.

Non-Squamous Non-Small Cell Lung Cancer Clinical Trial

Official title:
THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN.

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT01990261
Other study ID # ML28496
Secondary ID
Status Terminated
Phase N/A
First received October 31, 2013
Last updated May 4, 2016
Start date May 2013
Est. completion date September 2014

Study information
Verified date May 2016
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority Romania: National Agency of Medicines and Medical Devices
Study type Observational

Clinical Trial Summary

This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) patients treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.

Recruitment information / eligibility
Status Terminated
Enrollment 33
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults >/= 18 years

- Histologically documented locally advanced, metastatic, or recurrent non-small cell lung carcinoma with wild-type EGFR eligible for Tarceva treatment.

- At least one failed chemotherapy treatment.

Exclusion Criteria:

- Unknown EGFR mutation status

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Romania, 

Outcome
Type Measure Description Time frame Safety issue
Primary Efficacy: Overall survival (OS) 12 months No
Primary Safety: Incidence of adverse events (AE) 12 months No
Secondary Efficacy: OS rate according to prior chemotherapy treatment 12 months No
See also
  Status Clinical Trial Phase
Completed NCT02264990 - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers Phase 3
Completed NCT01328951 - A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy Phase 3
Completed NCT01664533 - An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy N/A
Completed NCT00976456 - Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer Phase 3
Completed NCT00988936 - Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug Phase 2
Completed NCT02596958 - Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants N/A
Completed NCT00974584 - A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00451906 - A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Phase 4
Completed NCT03329911 - A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer Phase 3
Not yet recruiting NCT03671538 - Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin N/A
Completed NCT01512420 - An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) N/A
Completed NCT01204697 - A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) Phase 2
Completed NCT01185847 - A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Phase 2
Terminated NCT00760929 - A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). Phase 2
Withdrawn NCT03319316 - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Phase 2
Recruiting NCT06334757 - Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Phase 2
Completed NCT01174563 - A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy Phase 2
Completed NCT01836133 - An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) N/A
Completed NCT01763671 - Paclitaxel-bevacizumab in Advanced Lung Cancer Phase 3
Completed NCT01609543 - A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Phase 4